In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 81 to 90 of 303

TitleTypeExpected publication date
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]Technology appraisal guidanceTBC
Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235Technology appraisal guidanceTBC
Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis (Review of TA648) [ID6480]Technology appraisal guidance
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]Technology appraisal guidanceTBC
Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation ID5073Technology appraisal guidance
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [ID6220]Technology appraisal guidanceTBC
Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]Technology appraisal guidanceTBC
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317Technology appraisal guidance
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]Technology appraisal guidance
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All